![PDF) A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function PDF) A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function](https://i1.rgstatic.net/publication/354759637_A_pre-specified_analysis_of_the_Dapagliflozin_and_Prevention_of_Adverse_Outcomes_in_Chronic_Kidney_Disease_DAPA-CKD_randomized_controlled_trial_on_the_incidence_of_abrupt_declines_in_kidney_function/links/614b39a7a3df59440ba46914/largepreview.png)
PDF) A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function
![PDF) Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials PDF) Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials](https://i1.rgstatic.net/publication/373120178_Estimated_lifetime_benefit_of_novel_pharmacological_therapies_in_patients_with_type_2_diabetes_and_chronic_kidney_disease_A_joint_analysis_of_randomized_controlled_clinical_trials/links/653e81710426ef6369e9fb84/largepreview.png)
PDF) Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials
![PDF) Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis PDF) Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis](https://i1.rgstatic.net/publication/349516607_Kidney_Cardiovascular_and_Safety_Outcomes_of_Canagliflozin_according_to_Baseline_Albuminuria_A_CREDENCE_Secondary_Analysis/links/60b4a3fca6fdcc1c66f4b4b6/largepreview.png)
PDF) Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis
![PDF) Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial PDF) Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial](https://i1.rgstatic.net/publication/350941425_Effects_of_dapagliflozin_on_mortality_in_patients_with_chronic_kidney_disease_a_pre-specified_analysis_from_the_DAPA-CKD_randomized_controlled_trial/links/607a8480907dcf667ba46201/largepreview.png)
PDF) Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
![PDF) Sustainable Development Goals relevant to kidney health: an update on progress | Ifeoma Ulasi - Academia.edu PDF) Sustainable Development Goals relevant to kidney health: an update on progress | Ifeoma Ulasi - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/52820670/mini_magick20190122-27874-1da2uw0.png?1548184540)